What question did this study set out to answer?

To quantitatively determine the packaging capacity and size limits of recombinant adeno-associated virus vectors for delivering therapeutic genes like CFTR.

November 10, 1996Human Gene Therapy

Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus

View Full Paper

Ask AI

Bookmark

Authors

JDJian-Yun DongArmy Medical University PFPeidong FanUniversity of North Carolina at Chapel Hill RFRaymond A. FrizzellUniversity of Pittsburgh

Discussion

Member takes

Implication

In vitro study demonstrates an optimal packaging limit between 4.1 and 4.9 kb for adeno-associated virus vectors, highlighting size constraints for cystic fibrosis gene therapy.

Key Points

To quantitatively determine the packaging capacity and size limits of recombinant adeno-associated virus vectors for delivering therapeutic genes like CFTR.
Constructed 12 recombinant adeno-associated virus (AAV) vectors ranging from 2 kb to 6 kb in length containing a chloramphenicol acetyltransferase (CAT) reporter gene.
Quantified packaging efficiency directly through viral particle DNA content assays and indirectly by measuring CAT reporter gene transfer into HeLa cells.
AAV vector packaging achieved optimal efficiency at genome sizes between 4.1 and 4.9 kb, with packaging efficiency declining sharply for genomes exceeding 4.9 kb up to an upper limit of 5.2 kb.
Genomes under 4.1 kb exhibited suboptimal efficiency, and genomes smaller than half the wild-type size packaged two copies per virion via a head-full mechanism.
Packaging the 4.5 kb minimal CFTR cDNA requires restricting the combined length of transcriptional elements and inverted terminal repeats to under 500 bp.

Cite This Study

Dong et al. (1996) studied this question.

synapsesocial.com/papers/6a0fb8872badbc352afe9a5c https://doi.org/10.1089/hum.1996.7.17-2101

View Full Paper

Ask AI

Bookmark

Implication

In vitro study demonstrates an optimal packaging limit between 4.1 and 4.9 kb for adeno-associated virus vectors, highlighting size constraints for cystic fibrosis gene therapy.

Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus

Discussion

Member takes

Implication

Key Points

Cite This Study

Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider